Who We Are
NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing therapies to treat the devastating effects of stroke and traumatic brain injury (TBI), including concussion. NTS is taking an innovative approach to the treatment of these conditions by addressing the fundamental underlying biological processes that enable the pathophysiological injury cascade.
What We Do
There are currently no therapies available to alleviate the cognitive, functional or neurobehavioral effects facing patients and their care givers following the acquired brain injuries of stroke or TBI. We work with the foremost scientific thought leaders, researchers, and clinicians in the field of neuroscience to develop a comprehensive view for treating these patients with significantly unmet therapeutic needs. By modulating the fundamental biological processes underlying the two conditions, leveraging both new molecular entities as well as repurposed drugs, and utilizing emerging technologies and biomarkers to identify the most appropriate subpopulations, we believe NTS will bring a much needed therapy to disease markets with growing patient populations and significant pent up demand.
NTS is pursuing a rich pipeline of opportunities to treat the life-altering effects immediately following an event as well as therapies to manage the persistent long-term deficits that are common with acquired brain injury.
NeuroTrauma Sciences LLC is a funded, privately held company.
Additional information on our investors may be made available upon request.